Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know

What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity treatment.

In this week's On The Pen Podcast, we're breaking down one of the biggest shifts happening in obesity medicine. We dive into new research on GLP-1 persistence, the early challenges facing Medicare's obesity drug rollout, and why pharmaceutical companies are racing to solve the problems patients have been talking about for years.

We also discuss the next generation of obesity therapies, including oral GLP-1s, implantable medications, muscle-preserving treatments, and why the future of obesity medicine may be less about losing more weight and more about helping patients stay healthy for the long term.

In this episode:
• Why patients who stop GLP-1 therapy often return
• The first weeks of Medicare's obesity medication coverage
• The future of oral GLP-1 medications
• New implant technology from Novo Nordisk
• Muscle-preserving obesity treatments
• Why patient experience is becoming the next frontier in obesity medicine

The goal of On The Pen has always been simple: translate complex obesity and diabetes news into information that helps you have better conversations with your doctor.

👇 What has been your biggest obstacle to staying on treatment? Insurance? Cost? Side effects? Tell us in the comments.

📰 Read more obesity medicine news:
https://OnThePen.com

📩 Subscribe to my free newsletter:
https://obesity.news

🔗 All my links:
https://OTPLINKS.com

👍 If you found this helpful, please Like, Subscribe, and Share this episode with someone navigating obesity, diabetes, or GLP-1 treatment.

#GLP1 #Obesity #WeightLoss #Zepbound #Mounjaro #Ozempic #Wegovy #ObesityMedicine #Type2Diabetes #OnThePen #Healthcare #Medicare #Podcast